|
10:45 AM-12:15 PM
Metro Toronto Convention Centre Room 709, Oral |
| Plaque Biofilm Control, Gingival Health Management |
| Chairpersons: M.W.B. ARAUJO and B. SÖDER |
| | |
| 0285 |
| Plaque Biofilm Penetration by Essential-Oil and Cpc Containing Mouthrinses
M.W.B. ARAUJO1, P. PAN1, R. LUX2, and W. SHI2, 1Johnson & Johnson Consumer & Personal Products Worldwide, Division of Johnson & Johnson Consumer Companies Inc, Morris Plains, NJ, USA, 2University of California - Los Angeles, USA |
| 0286 |
| Dental plaque, Microorganisms, Periodontitis, and Carotid Plaque, a Longitudinal Study
B. SÖDER1, M. YAKOB1, J. MEURMAN2, T. JOGESTRAND1, and P.-Ö. SÖDER3, 1Karolinska Institutet, Huddinge, Sweden, 2University of Helsinki, Finland, 3Karolinska Institutet, Stockholm, Sweden |
| 0287 |
| Evaluation of Antimicrobial Mouthrinses Using a Microplate-Based Flow-Through Biofilm Model
D. RICCI-NITTEL, and T. FOURRE, Johnson and Johnson Consumer & Personal Healthcare Products Worldwide - Division of Johnson & Johnson Companies, Morris Plains, NJ, USA |
| 0288 |
| Clinical Study Evaluating 0.454% Stannous Fluoride Dentifrice on Established Gingivitis
F. GARCIA-GODOY1, C. GARCIA-GODOY1, J.M. DUNAVENT2, and R.W. GERLACH2, 1Nova Southeastern University, Ft. Lauderdale, FL, USA, 2The Procter and Gamble Company, Mason, OH, USA |
| 0289 |
| A meta-analysis of gum health studies: 3-month versus 6-month results
T.F. COX, and F. SCHÄFER, Unilever Oral Care, Bebington, Wirral, United Kingdom |
| 0290 |
| Placebo-Controlled Clinical Trial of 0.07% CPC Rinse on Induced Gingivitis
J.J. WITT1, R.D. GIBB1, A.D. LOGUE1, R.W. GERLACH1, and L. ARCHILA2, 1The Procter and Gamble Company, Mason, OH, USA, 2University of Texas - San Antonio / Health Science Ctr, USA |
|
Back to the: Oral Health Research Program
|
|
